Infusion Center

Regeneron EUA info sheet for patients

REGEN-COV INFUSION FOR TREATMENT

EUA is for the treatment of mild to moderate COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

MUST HAVE ALL OF THE FOLLOWING

1. Positive SARS CoV-2 test
2. Within 10 days of initial symptom onset
3. ≥12 years old
4. ≥88 lbs or 40 kg
5. SPO2 ≥94%

AND AT LEAST ONE OF THE FOLLOWING

• Age ≥65 years of age
• BMI >25 kg/m2 , or if age 12-17, BMI ≥85th percentile
• Chronic kidney disease
• Diabetes
• Immunosuppressive disease or immunosuppressive        treatment
• Cardiovascular disease (including congenital heart disease) or hypertension
• Chronic lung diseases (e.g. COPD, moderate to severe asthma, interstitial lung disease, cystic fibrosis and pulmonary hypertension)
• Sickle cell disease
• Neurodevelopmental disorders (e.g., cerebral palsy), genetic or metabolic syndromes and severe congenital anomalies
• Medical-related technological dependence, e.g., tracheostomy or gastrostomy.

OB APPROVAL NEEDED IF PREGNANT